Last edition
News about Global Pharma
The data to be presented span Merck’s broad HIV portfolio, including investigational therapies for both treatment and prevention. The presentations will feature new clinical results from Phase 1, 2, and 3 studies evaluating the efficacy, safety, and pharmacokinetics of the company’s next-generation antiviral candidates.
Global Pharma | 13/10/2025 | By Dineshwori | 178
Chugai Pharma concludes licence agreement with Roche for CT-388
Chugai Pharmaceutical has signed a licensing deal with F. Hoffmann-La Roche for CT-388, a long-acting GLP-1/GIP receptor agonist for obesity and type-II diabetes, granting Chugai exclusive development and marketing rights in Japan.
Global Pharma | 11/10/2025 | By Dineshwori | 354
Johnson & Johnson MedTech Launches CORE-VA Registry to Advance Ventricular Arrhythmia Care
Johnson & Johnson MedTech, in collaboration with the Heart Rhythm Clinical and Research Solutions, has unveiled a new initiative aimed at improving outcomes for patients with life-threatening heart rhythm disorders.
Global Pharma | 11/10/2025 | By Dineshwori | 201
AstraZeneca has announced a historic agreement with President Donald Trump’s administration to lower the cost of prescription medicines for American patients while strengthening the nation’s biopharmaceutical innovation base.
Global Pharma | 11/10/2025 | By Dineshwori | 117
Shuttle Pharmaceuticals Signs LOI to Acquire Molecule.ai in USD 10 Million Deal
US-based specialty pharmaceutical company Shuttle Pharmaceuticals Holdings has signed a non-binding Letter of Intent (LOI) to acquire Molecule.ai, an advanced artificial intelligence firm revolutionising drug discovery and development.
Global Pharma | 10/10/2025 | By Dineshwori | 216
Lonza has received Swissmedic approval for its new state-of-the-art aseptic filling line in Stein (CH), designed for biologics and highly potent products, including antibody-drug conjugates (ADCs).
Global Pharma | 10/10/2025 | By Dineshwori | 118
Novo Nordisk to Acquire Akero Therapeutics Alongside Promising MASH Therapy Efruxifermin
Danish pharma giant Novo Nordisk has signed a definitive agreement to acquire Akero Therapeutics, a San Francisco-based clinical-stage biopharmaceutical company focused on developing innovative therapies for serious metabolic diseases.
Global Pharma | 10/10/2025 | By Dineshwori | 207
Jubilant HollisterStier LLC (JHS) — a wholly owned subsidiary of Jubilant Pharmova and a leading North American contract manufacturer specialising in sterile injectables — has launched a new Sterile Fill & Finish line, its third at the Spokane manufacturing facility in Washington, USA.
Global Pharma | 10/10/2025 | By Dineshwori | 189
Thermo Fisher Launches Molecular Microscope to Assess Lung Transplant Rejection
Thermo Fisher’s new Molecular Microscope Diagnostic System for Lung (MMDx Lung) leverages the power of Machine Learning (ML) to profile gene expression data from lung biopsies, comparing each new sample to a reference set of over 896 lung biopsies.
Global Pharma | 10/10/2025 | By Dineshwori
Jascayd is the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication. This represents a novel mechanism of action that exerts both antifibrotic and immunomodulatory effects, thereby slowing the decline in lung function in IPF patients.
Global Pharma | 10/10/2025 | By Dineshwori | 253
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy